An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

• Published in: Arthritis research & therapy Vol. 21; no. 1; pp. 84 - 10
• Main Authors: Cohen, Stanley, Pablos, Jose L., Pavelka, Karel, Müller, Gerard Anton, Matsumoto, Alan, Kivitz, Alan, Wang, Hui, Krishnan, Eswar
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29.03.2019; BioMed Central; BMC
• Subjects: ABP 501; Adalimumab; Adalimumab - adverse effects; Adalimumab - therapeutic use; Adult; Age; Aged; Antibodies; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis; Arthritis, Rheumatoid - drug therapy; Biological products; Biosimilar; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - therapeutic use; C-reactive protein; Cost control; Cytotoxicity; Dosage and administration; Double-Blind Method; Drug Administration Schedule; Drug dosages; Drug therapy; Efficacy; FDA approval; Female; Humans; Immunoglobulins; Immunotherapy; Labels; Long-term safety; Male; Medical research; Middle Aged; Monoclonal antibodies; Nasopharyngitis - chemically induced; Patient outcomes; Patients; Pediatrics; Prescription drugs; Psoriasis; Regulatory agencies; Regulatory approval; Rheumatoid arthritis; Rheumatoid factor; Rheumatology; TNF inhibitors; Treatment Outcome; Tumor necrosis factor-TNF; United States; United States > US; Efficacy; Long-term safety; Adalimumab; Rheumatoid arthritis; ABP 501; Biosimilar
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-019-1857-3

ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. ClinicalTrial.gov, NCT02114931.